Multiple Myeloma

Published by Andy LoCascio at July 6, 2018

Multiple Myeloma

November, 2022 Treatment Possibilities for R/R Multiple Myeloma After BCMA-Directed CAR T-Cell Therapy
https://www.targetedonc.com/view/treatment-possibilities-for-r-r-multiple-myeloma-after-bcma-directed-car-t-cell-therapy

November, 2022 Pfizer’s multiple myeloma treatment granted FDA Breakthrough Therapy Designation
https://www.printfriendly.com/p/g/PUpN7B

November, 2022 FDA Grants Breakthrough Therapy Designation to Elranatamab for Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-elranatamab-for-relapsed-refractory-multiple-myeloma

November, 2022 Year in Review: Multiple Myeloma
https://www.medpagetoday.com/hematologyoncology/myeloma/101517

October, 2022 Janssen’s Tecvayli granted FDA approval for multiple myeloma
https://www.pmlive.com/pharma_news/janssens_tecvayli_granted_fda_approval_for_multiple_myeloma_1479795

Overview of Multiple Myeloma

Multiple myeloma is a hematologic (blood) malignancy that forms in a type of white blood cell called a plasma cell. Plasma cells are a type of fully developed B lymphocytes, a group of white blood cells that originate in the bone marrow and play an important role in the immune system. This disease is called “multiple” myeloma because tumors often develop in more than one location in the bone marrow.

In myeloma, one population of normal antibody-producing plasma cells transform into malignant myeloma cells and replicate uncontrollably. Instead of producing healthy germ fighting antibodies, the malignant cells produce abnormal proteins (such as monoclonal M- protein) that crowd out and inhibit the production of normal blood cells and antibodies in the bone marrow.

Symptoms associated with Multiple Myeloma “CRAB” hyperCalcemia, Renal insufficiency, Anemia, Bone lesions: The immune system is negatively affected by the overproduction of one antibody and can no longer effectively target all pathogens. As the plasma cells continue to multiply, damage to organs can occur, specifically the kidneys. Anemia results when the myeloma prevents the bone marrow from producing red blood cells. Osteolytic lesions (soft spots in the bone) by melanoma cells often replace solid healthy bone marrow.

Treatment for Multiple Myeloma

Clinical Trials for Multiple Myeloma

National Cancer Institutes Multiple Myeloma Trial Results
http://www.cancer.gov/clinicaltrials/results/type/multiple-myeloma

ClinicalTrials.gov Clinical trial search
http://clinicaltrials.gov/ct2/?ui=D009101&recruiting=true

International Myeloma Foundation Clinical Trial Research
http://myeloma.org/IndexPage.action?tabId=26&menuId=207&indexPageId=21&parentMenuItemId=207&categoryId=438

Cancer.net Multiple Myeloma Clinical Trials
http://www.cancer.net/cancer-types/multiple-myeloma/about-clinical-trials

More Multiple Myeloma Opportunities for Research & Education
http://www.mmore.org/ClinicalTrials.html

Trial Check: service from the Leukemia & Lymphoma Society
https://www.eviticlinicaltrials.com/cancertrialshelp/LLSMembership.aspx?AppMode=0

MMRF Multiple Myeloma Research Foundation Clinical Trial Search
https://myeloma.trialx.com/ask/

Additional Educational Resources for Multiple Myeloma

American Cancer Society
http://www.cancer.org/cancer/index

American Society of Hematology
http://www.hematology.org/patients/

Be The Match Bone Marrow or Cord Blood Transplant Resource
http://www.marrow.org/For-Patients-and-Families/

E Cancer Education
http://www.cancereducation.com/

The Multiple Myeloma Research Consortium
http://themmrc.org/

The Leukemia & Lymphoma Society
http://www.lls.org/

Signal Genetics’ MyPRS
https://www.signalgenetics.com/patients_my_prs.html